Clorpropamida L.CH. Side effects

• Side effects of Clorpropamida L.CH. in details
• Clorpropamida L.CH. contraindications
• Clorpropamida L.CH. reviews

What are the possible side effects of Clorpropamida L.CH.?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Hypoglycemia, or low blood sugar, is the most common side effect of Clorpropamida L.CH.. Symptoms include headache, hunger, weakness, sweating, tremors, irritability, trouble concentrating, rapid breathing, fast heartbeat, fainting, or seizure (severe hypoglycemia can be fatal). Carry hard candy or glucose tablets with you in case you have low blood sugar.

Stop taking Clorpropamida L.CH. and call your doctor at once if you have a serious side effect such as:

• easy bruising or bleeding, unusual weakness;
• pale skin, fever, confusion;
• trouble concentrating, memory problems, feeling unsteady, hallucinations;
• feeling light-headed, fainting;
• nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
• throbbing headache, sweating, severe nausea, trouble breathing, fast or pounding heartbeats, blurred vision, spinning sensation; or
• severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Less serious side effects may include:

• mild nausea, vomiting, diarrhea;
• mild hunger; or
• mild skin rash, redness, or itching.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects of Clorpropamida L.CH. in details

The majority of the side-effects have been dose-related, transient, and have responded to dose reduction or withdrawal of the medication. However, clinical experience thus far has shown that, as with other sulfonylureas some side-effects associated with hypersensitivity may be severe and deaths have been reported in some instances.

Clorpropamida L.CH. has a somewhat higher reported incidence of side-effects than tolbutamide.

Certain untoward reactions associated with idiosyncrasy of hypersensitivity have occurred, including jaundice, skin eruptions rarely progressing to erythema multiforme and exfoliative dermatitis, and probably depression of formed elements of the blood, showing no direct relationship to the size of the dose. They occur characteristically during the first six weeks of therapy. With a few exceptions, these manifestations have been mild and readily reversible on the withdrawal of the drug. Rare cases of phototoxic reactions

have been reported.

The more severe manifestations may require other therapeutic measures, including corticosteroid therapy. Clorpropamida L.CH.; should be discontinued promptly when the development of sensitivity is suspected. Jaundice has been reported, and is usually promptly reversible on discontinuance of therapy.

Skin rash may be either the only manifestation of sensitivity, or occur in association with jaundice, frequently preceding it. Low grade fever and eosinophilia may also occur in association with, or preceding the development of clinical jaundice. Rarely, severe diarrhoea, sometimes accompanied by bleeding into the lower bowel and due to nonspecific proctocolitis, has been associated with other hypersensitivity manifestations, particularly jaundice, skin rash, or both. The occurrence, singly or together, of any of these hypersensitivity manifestations, should constitute an indication for prompt termination of the drug and such other therapeutic, measures as are indicated by the circumstances, should be instituted.

Leukopenia, thrombocytopenia and mild anemia, which occur occasionally, are generally benign and revert to normal, following cessation of the drug, leukopenia of mild degree, and not associated with a shift in the differential count, may be transient and frequently reverts to normal even while the drug is continued.

Cases of aplastic anemia and agranulocytosis, generally similar to blood dyscrasias associated with other sulfonylureas have been reported. Lymphocytosis appears to be of no clinical significance. Dose-related side-effects previously mentioned are generally transient and not of a serious nature and would include anorexia, nausea, vomiting, and epigastric discomfort as evidence of gastro-intestinal intolerance, and various vague neurologic symptoms, particularly weakness and paraesthesias. These manifestations are generally a direct function of dosage and were reported much more frequently during the early clinical history of the drug when some clinicians employed relatively high doses.

These side-effects are reversible on reduction of the daily dosage, or if necessary, by withdrawal of the medication.

Clorpropamida L.CH. may infrequently induce a syndrome of inappropiate secretion of antidiuretic hormone characterized by water retention, hyponatraemia, and central nervous system signs.

Since animal studies suggest that the action of barbiturates may be prolonged by therapy with Clorpropamida L.CH., barbiturates should be employed with caution.

Similarly, studies showing an exaggerated hypoglycaemic effect of Clorpropamida L.CH. in adrenalectomised animals suggest cautious use in patients with Addison’s disease. In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol. Caution should be exercised when antibacterial sulfonamides, phenylbutazone, salicylates, probenecid, dicoumarol, or MAO inhibitors are administered concomitantly with Clorpropamida L.CH. as hypoglycaemia resultant from either potentiation or accumulation of sulfonylureas has been reported. Compounds that may diminish the hypoglycaemic effect and thus cause an increase in the dosage requirement of Clorpropamida L.CH. include rifampicin and the thiazide diuretics.

Clorpropamida L.CH. should not be used to replace dietetic therapy in the obese.

Ether and suxamethonium antagonise the hypoglycaemic action of Clorpropamida L.CH..

What is the most important information I should know about Clorpropamida L.CH.?

• Clorpropamida L.CH. may cause drowsiness, dizziness, blurred vision, or lightheadedness. These effects may be worse if you take it with alcohol or certain medicines. Use Clorpropamida L.CH. with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
• Do not drink alcohol while you are taking Clorpropamida L.CH.. It may increase the risk of low blood sugar. Rarely, alcohol may interact with Clorpropamida L.CH. and cause a serious reaction with symptoms such as flushing, nausea, vomiting, dizziness, or stomach pain. Discuss any questions or concerns with your doctor.
• Carry an ID card at all times that says you have diabetes. Check your blood sugar levels as directed by your doctor. If they are often higher or lower than they should be and you take Clorpropamida L.CH. exactly as prescribed, tell your doctor.
• Proper diet, regular exercise, and regular blood sugar testing are important for best results with Clorpropamida L.CH.. Follow the diet and exercise program given to you by your health care provider.
• It may be harder to control your blood sugar during times of stress such as fever, infection, injury, or surgery. Talk with your doctor about how to control your blood sugar if any of these occur. Do not change the dose of your medicine without checking with your doctor.
• Clorpropamida L.CH. may cause low blood sugar levels. Low blood sugar may make you anxious, sweaty, weak, dizzy, drowsy, or faint. It may also make your heart beat faster; make your vision change; give you a headache, chills, or tremors; or make you more hungry. It is a good idea to carry a reliable source of glucose (eg, tablets or gel) to treat low blood sugar. If this is not available, you should eat or drink a quick source of sugar like table sugar, honey, candy, orange juice, or non-diet soda. This will raise your blood sugar level quickly. Tell your doctor right away if this happens. To prevent low blood sugar, eat meals at the same time each day and do not skip meals.
• Risk of low blood sugar may be increased by severe or prolonged exercise, drinking alcohol, or skipping meals.
• Clorpropamida L.CH. is a sulfonylurea. It may increase the risk of death from heart disease. Talk with your doctor about the benefits and risks of this or other therapies to treat your condition.
• Clorpropamida L.CH. may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Clorpropamida L.CH.. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.
• Tell your doctor or dentist that you take Clorpropamida L.CH. before you receive any medical or dental care, emergency care, or surgery.
• Lab tests, including fasting blood glucose and hemoglobin A, may be performed while you use Clorpropamida L.CH.. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
• Use Clorpropamida L.CH. with caution in the ELDERLY; they may be more sensitive to its effects, especially low blood sugar levels and low blood sodium levels.
• Clorpropamida L.CH. should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.
• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Clorpropamida L.CH. while you are pregnant. Clorpropamida L.CH. should not be used for at least 1 month before the expected delivery date because it may cause low blood sugar in the baby. Clorpropamida L.CH. is found in breast milk. Do not breast-feed while taking Clorpropamida L.CH..

When used for long periods of time, Clorpropamida L.CH. may not work as well. If your blood sugar has been under control and then becomes hard to manage, contact your doctor. Do not change the dose of your medicine without checking with your doctor.

Clorpropamida L.CH. contraindications

Do not use this medication if you are allergic to Clorpropamida L.CH., or if you are in a state of diabetic ketoacidosis. Call your doctor for treatment with insulin.

Before taking Clorpropamida L.CH., tell your doctor if you have kidney or liver disease, a disorder of your pituitary or adrenal glands, a history of heart disease, or if you are malnourished.

Certain oral diabetes medications may increase your risk of serious heart problems. However, not treating your diabetes can damage your heart and other organs. Talk to your doctor about the risks and benefits of treating your diabetes with Clorpropamida L.CH..

Low blood sugar (hypoglycemia) can occur if you skip a meal, exercise too long, drink alcohol, or are under stress. Symptoms include headache, hunger, weakness, sweating, tremors, irritability, or trouble concentrating. Carry hard candy or glucose tablets with you in case you have low blood sugar. Other sugar sources include orange juice and milk. Be sure your family and close friends know how to help you in an emergency.

Signs of blood sugar that is too high (hyperglycemia) may include increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, and weight loss. Your blood sugar will need to be checked often, and you may need to adjust your Clorpropamida L.CH. dose.

Clorpropamida L.CH. is only part of a complete program of treatment that may also include diet, exercise, weight control, foot care, eye care, and testing your blood sugar. Follow your diet, medication, and exercise routines very closely. Changing any of these factors can affect your blood sugar levels.

References

1. DailyMed. "CHLORPROPAMIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. DTP/NCI. "NSC626720: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
3. European Chemicals Agency - ECHA. "Chlorpropamide: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology